Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] A structural view of the SARS-CoV-2 virus and its assembly
NJ Hardenbrook, P Zhang - Current opinion in virology, 2022 - Elsevier
Highlights•Structural biology plays a vital role in SARS-CoV-2 vaccine and treatment.•High-
resolution structures of SARS-CoV-2 proteins and complexes have been obtained.•In situ …
resolution structures of SARS-CoV-2 proteins and complexes have been obtained.•In situ …
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA. 1, BA. 2, and BA. 4/5 and diverse sarbecoviruses
Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
Seasonal coronavirus–specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19
M Aguilar-Bretones, BM Westerhuis… - The Journal of …, 2021 - Am Soc Clin Investig
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus
disease 2019 (COVID-19). Little is known about the interplay between preexisting immunity …
disease 2019 (COVID-19). Little is known about the interplay between preexisting immunity …
Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies
NZ Zabidi, HL Liew, IA Farouk, A Puniyamurti, AJW Yip… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Abstract The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
health crisis that demands the timely creation of new therapeutics and viral detection. Owing …
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
L Hanke, H Das, DJ Sheward… - Nature …, 2022 - nature.com
Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …
spike have therapeutic promise, but emerging variants show the potential for virus escape …
Protease-responsive peptide-conjugated mitochondrial-targeting AIEgens for selective imaging and inhibition of SARS-CoV-2-infected cells
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a serious threat to
human health and lacks an effective treatment. There is an urgent need for both real-time …
human health and lacks an effective treatment. There is an urgent need for both real-time …